Navigation Links
Nektar Therapeutics Reports Third Quarter 2011 Financial Results

SAN FRANCISCO, Calif., Nov. 2, 2011 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the third quarter ended September 30, 2011.

Cash, cash equivalents, and investments at September 30, 2011 were $458.0 million as compared to $315.9 million at December 31, 2010.

Revenue for the third quarter of 2011 was $27.1 million, a decrease as compared to $37.9 million in the third quarter of 2010 primarily as a result of the completion as of December 31, 2010 of the amortization of the $125.0 million upfront payment received in 2009 from AstraZeneca for the NKTR-118 and NKTR-119 license agreement.  

"Nektar is highly focused on continuing to advance our important proprietary drug candidates in pain and cancer," said Howard W. Robin, President and Chief Executive Officer of Nektar. "AstraZeneca's Phase 3 KODIAC program for NKTR-118 for opioid-induced constipation is continuing on-track with AZ targeting regulatory filing in 2013.  We are targeting the start of the Phase 3 BEACON study for NKTR-102 in metastatic breast cancer before year-end.  NKTR-181, our novel opioid candidate to treat chronic pain, is moving rapidly through Phase 1 clinical development and we plan to announce topline data before year-end.  Finally, we plan to file an IND for NKTR-192, our new clinical candidate to treat acute pain, in the first quarter of 2012." 

Total operating costs and expenses in the third quarter of 2011 were $48.4 million, an increase compared to $44.2 million in the third quarter of 2010. The increase is primarily a result of higher development expenses related to the advancement of multiple programs in clinical development.  Research and development expense increased to $31.0 million in the third quarter of 2011 as compared to $27.7 million for the same quarter in 2010.  General and administrative expense was $12.4 million in the third quarter of 2011 as compared to $10.2 million in the third quarter of 2010.  

Net loss for the third quarter ended September 30, 2011 was $24.1 million or $0.21 loss per share.

The company also announced upcoming presentations at medical meetings and scientific congresses scheduled for the fourth quarter of 2011:

Chemotherapy Foundation Symposium XXIX: Innovative Cancer Therapy for Tomorrow, New York, NY:

  • Session Title: "Evaluating Single-Agent NKTR-102 in Metastatic Breast Cancer"
  • Presenter: Edith Perez, MD
  • Session Type: Oral
  • Program Track: Breast Cancer
  • Date and Time: November 10, 2011, 1:25 PM Eastern Time

  • Neuroscience 2011: Society for Neuroscience Annual Meeting, Washington, DC:Preclinical data for NKTR-192, a new opioid drug candidate being developed to treat acute pain, will be presented.

  • Abstract Title: "Pharmacological characterization of an orally active opioid analgesic with rapid onset of activity and low abuse liability." Harrison, S., et al.  
  • Abstract/Poster Number: #178.10/NN20
  • Session Title/Track:  "Pharmacology Relevant to Pain, Addiction, and Development"
  • Date and Time: Nov 13, 2011, 8:00 AM - 12:00 PM Eastern Time

  • 2011 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, San Francisco, CAPreclinical data for NKTR-102 in ovarian cancer will be presented.

  • Abstract Title: "Strong synergistic activity of NKTR-102 - pegylated liposomal doxorubicin (PLD) combination therapy in a nonclinical model of platinum-resistant A2780 human ovarian cancer." Hoch, et al.
  • Abstract/Poster Number: C209
  • Session Title/Track:  Topoisomerase Inhibitors
  • Date and Time: Nov 15, 2011, 12:30 PM - 2:30 PM Pacific Time

  • Conference Call to Discuss Third Quarter 2011 Financial ResultsNektar management will host a conference call to review the results beginning at 5:00 p.m. Eastern Time (ET)/2:00 p.m. Pacific Time (PT) today, Wednesday, November 2, 2011.

    The press release and a live audio-only Webcast of the conference call can be accessed through a link that is posted on the home page and Investor Relations section of the Nektar website: The web broadcast of the conference call will be available for replay through December 1, 2011.

    To access the conference call, follow these instructions:

    Dial: (866) 203-3436 (U.S.); (617) 213-8849 (international)
    Passcode: 16610535 (Nektar Therapeutics is the host)

    An audio replay will also be available shortly following the call through Thursday, December 1, 2011 and can be accessed by dialing (888) 286-8010 (U.S.); or (617) 801-6888 (international) with a passcode of 41636531.

    In the event that any non-GAAP financial measure is discussed on the conference call that is not described in the press release, or explained on the conference call, related information will be made available on the Investor Relations page at the Nektar website as soon as practical after the conclusion of the conference call.

    About NektarNektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms. Nektar has a robust R&D pipeline of potentially high-value therapeutics in oncology, pain and other therapeutic areas. In the area of pain, Nektar has an exclusive worldwide license agreement with AstraZeneca for NKTR-118, an investigational drug candidate, being evaluated in Phase 3 clinical studies as a once-daily, oral tablet for the treatment of opioid-induced constipation.  The agreement also includes NKTR-119, an earlier stage development program that is a co-formulation of NKTR-118 and an opioid.  NKTR-181, a novel mu-opioid analgesic molecule wholly-owned by Nektar, is being evaluated in Phase 1 clinical studies.  In oncology, NKTR-102, a novel proprietary topoisomerase I-inhibitor, is being evaluated in Phase 2 clinical studies for the treatment of breast, ovarian and colorectal cancers.

    Nektar's technology has enabled seven approved products in the U.S. or Europe through partnerships with leading biopharmaceutical companies, including UCB's Cimzia® for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS® for hepatitis C and Amgen's Neulasta® for neutropenia. Additional development stage products that leverage Nektar's proprietary technology platform include peginesatide, for which Affymax and partner Takeda submitted an NDA to the FDA in May 2011, and Baxter's BAX 855, a long-acting PEGylated rFVIII program planned to enter Phase 1 clinical development in 2011.

    Nektar is headquartered in San Francisco, California, with additional R&D operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at

    This press release contains forward-looking statements including but not limited to Nektar's plans to initiate the Phase 3 BEACON study for NKTR-102 in metastatic breast cancer before year-end, plans to complete a Phase 1 clinical study for NKTR-181 and announce those results before year end, AstraZeneca's plans for regulatory filings in 2013, Baxter's plans to advance BAX 855 into Phase 1 clinical development prior to year end, Nektar's plan to file an investigational new drug application for NKTR-192 in the first quarter of 2012, and the value and potential of Nektar's R&D pipeline.  These forward-looking statements involve numerous risks and uncertainties, including but not limited to: (i) Nektar's product candidates and those of its collaboration partners are in various stages of clinical development and the risk of failure is high and can unexpectedly occur at any stage prior to regulatory approval for numerous reasons including safety and efficacy findings even after positive findings in preclinical and clinical studies; (ii) the timing of the commencement or end of clinical trials, the announcement of clinical trial results, and the commercial launch of our drug candidates may be delayed or unsuccessful due to regulatory delays, slower than anticipated patient enrollment, manufacturing challenges, changing standards of care,  evolving regulatory requirements, clinical trial design, clinical outcomes, competitive factors, or delay or failure in ultimately obtaining regulatory approval in one or more important markets; (iii) scientific discovery of new medical breakthroughs is an inherently uncertain process and the future success of the application of Nektar's technology platform to potential new drug candidates is therefore highly uncertain and unpredictable and one or more research and development programs could fail; (iv) Nektar's patent applications for its proprietary or partner product candidates may not issue, patents that have issued may not be enforceable, or additional intellectual property licenses from third parties may be required in the future; (v) the outcome of any future intellectual property or other litigation related to Nektar's proprietary product candidates or complex commercial agreements; and (vi) certain other important risks and uncertainties set forth in Nektar's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 5, 2011.  Actual results could differ materially from the forward-looking statements contained in this press release.  Nektar undertakes no obligation to update forward-looking statements, whether as a result of new information, future events or otherwise.Nektar Investor Inquiries:Jennifer Ruddock/Nektar Therapeutics

    (415) 482-5585Susan Noonan/SA Noonan Communications, LLC

    (212) 966-3650Nektar Media Inquiries:Karen Bergman/BCC Partners

    (650) 575-1509 Michelle Corral/BCC Partners

    (415) 794-8662NEKTAR THERAPEUTICSCONDENSED CONSOLIDATED BALANCE SHEETS(In thousands)(Unaudited)ASSETSSeptember 30, 2011December 31, 2010

    (1)Current assets:Cash and cash equivalents

    7,755Short-term investments

    223,479298,177Accounts receivable


    10,6547,266Other current assets

    7,5655,679Total current assets

    297,620353,979Long-term investments

    191,478-Property and equipment, net


    76,50176,501Other assets

    845972Total assets

    521,225LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:Accounts payable

    7,194Accrued compensation

    11,7609,252Accrued expenses

    11,7778,540Accrued clinical trial expenses

    13,61212,144Deferred revenue, current portion

    19,98220,584Convertible subordinated notes, current portion

    214,955-Other current liabilities

    4,7816,394Total current liabilities

    279,04264,108Convertible subordinated notes

    -214,955Capital lease obligations

    15,25017,014Deferred revenue

    113,045124,763Deferred gain

    3,4974,152Other long-term liabilities

    6,4625,571Total liabilities

    417,296430,563Commitments and contingenciesStockholders' equity:Preferred stock

    --Common stock

    119Capital in excess of par value

    1,592,8031,354,232Accumulated other comprehensive income (loss)

    (987)968Accumulated deficit

    (1,361,030)(1,264,547)Total stockholders' equity

    230,79790,662Total liabilities and stockholders' equity

    521,225(1) The consolidated balance sheet at December 31, 2010 has been derived from the audited financial statements at that date but does not include all of the information and notes required by generally accepted accounting principles in the United States for complete financial statements. NEKTAR THERAPEUTICSCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(In thousands, except per share information)(Unaudited)Three Months EndedNine Months EndedSeptember 30, September 30,2011201020112010Revenue:Product sales and royalties

    $  10,222$  7,230$  26,023$  21,968License, collaboration and other

    16,84630,69529,67591,757Total revenue

    27,06837,92555,698113,725Operating costs and expenses:Cost of goods sold

    5,0386,24516,44115,430Research and development

    31,01827,72493,46476,610General and administrative

    12,35010,18135,26229,401Total operating costs and expenses

    48,40644,150145,167121,441Loss from operations

    (21,338)(6,225)(89,469)(7,716)Non-operating income (expense):Interest income

    6223691,5831,225Interest expense

    (2,543)(2,826)(7,698)(8,686)Other income (expense), net

    (717)249(599)436Total non-operating expense

    (2,638)(2,208)(6,714)(7,025)Loss before provision for income taxes

    (23,976)(8,433)(96,183)(14,741)Provision for income taxes

    92278300617Net loss

    $ (24,068)$ (8,711)$ (96,483)$ (15,358)Basic and diluted net loss per share

    (0.21)$   (0.09)$
    (0.16)Weighted average shares outstanding used in computing basic and diluted net loss per share

    114,41394,213112,43593,972NEKTAR THERAPEUTICSCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(In thousands)(Unaudited)Nine Months Ended September 30,20112010Cash flows from operating activities:Net loss

    $   (96,483)$ (15,358)Adjustments to reconcile net loss to net cash used in operating activities:Depreciation and amortization

    11,42412,499Stock-based compensation

    14,50112,716Other non-cash transactions

    967(176)Changes in operating assets and liabilities:Accounts receivable


    (3,388)(4,989)Other assets

    (1,750)1Accounts payable

    (4,200)1,755Accrued compensation

    2,508500Accrued expenses

    6,2384,090Accrued clinical trial expenses

    1,468(1,408)Deferred revenue

    (12,320)(83,107)Other liabilities

    (2,681)(2,049)Net cash used in operating activities

    $   (71,528)$ (76,278)Cash flows from investing activities:Purchases of investments

    (627,529)(315,160)Sales of investments

    218,66010,290Maturities of investments

    290,810360,906Purchases of property and equipment

    (8,294)(22,160)Net cash (used in) provided by investing activities

    $ (126,353)$  33,876Cash flows from financing activities:Payments of loan and capital lease obligations

    (1,431)(1,119)Issuance of common stock, net of issuance costs

    224,0727,142Net cash provided by financing activities

    $  222,641$
    ,023Effect of exchange rates on cash and cash equivalents

    493(312)Net increase (decrease) in cash and cash equivalents

    25,253$ (36,691)Cash and cash equivalents at beginning of period

    17,75549,597Cash and cash equivalents at end of period

    43,008$  12,906

    SOURCE Nektar Therapeutics
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
    2. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
    3. Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients
    4. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
    5. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
    6. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
    7. Nektar Announces Positive Results from Phase 2 Study of Oral NKTR-118 in Patients with Opioid-Induced Constipation (OIC)
    8. Nektar Therapeutics Reports Second Quarter 2009 Financial Results
    9. Nektar Presents Data Demonstrating Favorable Oral Bioavailability and Drug-Drug Interaction Profile for NKTR-118
    10. Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Senior Vice President and Chief Medical Officer
    11. Nektar Presents New Preclinical Data on NKTR-181 at Anesthesiology 2010
    Post Your Comments:
    (Date:11/26/2015)... 2015 --> ... potential att använda SyMRI för att hitta ... patienter med multipel skleros (MS) eller hjärntumörmetastaser ... AB för att kunna använda SyMRI Research ... SyMRI kan man generera flera konstrastbilder från ...
    (Date:11/26/2015)... November 26, 2015 ... adds "Global Repaglinide Industry ... Report on China Repaglinide Market, 2010-2019" ... data and information to its online ... . --> ...
    (Date:11/26/2015)... 2015 ) ... "Radioimmunoassay Market by Type (Reagents & Kits, ... Clinical Diagnostic Labs), Application (Research, Clinical Diagnostics), ... report to their offering. --> ... of the "Radioimmunoassay Market by Type ...
    Breaking Medicine Technology:
    (Date:11/26/2015)... Bangalore, Karnataka (PRWEB) , ... ... ... an innovative online platform for mental health and wellness consultation, has collaborated ... self-empowerment, to holistically address their reader’s queries on topics on mental and ...
    (Date:11/25/2015)... Indianapolis, IN (PRWEB) , ... November 25, 2015 ... ... clean water accessible for all, Water For Empowerment ™ attracts volunteers together ... on clean water by empowering women as key stakeholders in the process. The ...
    (Date:11/25/2015)... Neb. (PRWEB) , ... November 25, 2015 , ... ... staffing companies, has been recognized once again for its stellar workplace culture with ... to Work.” , Medical Solutions’ Cincinnati office was named a finalist ...
    (Date:11/25/2015)... ... , ... Ministers, senior government and UN agencies, representatives from ... Excellence, and public R&D institutions, civil societies and other partners gathered today at ... Network for Drugs and Diagnostics Innovation, ANDI, Stakeholders Meeting. The three- day meeting ...
    (Date:11/25/2015)... Angeles, CA (PRWEB) , ... November 25, 2015 , ... ... da Vinci surgical robot is being more and more widely heralded as a breakthrough ... assisted da Vinci method has over traditional laparoscopic surgery is that it can greatly ...
    Breaking Medicine News(10 mins):